Aurion Biotech

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,

Aurion Biotech, a privately-owned company with offices in Seattle, Tokyo and Cambridge, Mass., is riding high after releasing positive topline data from its allogeneic cell therapy, AURN001, for corne

The series C venture capital round that Tessera Therapeutics announced on 19 April – totaling more than $300m, the company said – shows that investors continue to be willing to invest large sums in